SCHEMBL1469205

SCHEMBL1469205

Nc1ccc(C(=O)Cl)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
POLB P06746 1/20 0.54
TSHR P16473 5/20 0.48
CYP3A4 P08684 4/20 0.48
THRB P10828 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
CASP1 P29466 1/20 0.48
RECQL P46063 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MAPK1 P28482 1/20 0.46
LRRK2 Q5S007 1/20 0.44
ESR2 Q92731 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11879283 0.98 ALDH1A1 (0.53) ALDH1A1POLBTSHRCYP3A4THRB
SCHEMBL437529 0.84 ALDH1A1 (0.66) ALDH1A1POLBTSHRCYP3A4THRB
SCHEMBL879015 0.83 ALDH1A1 (0.54) ALDH1A1POLBTSHRCYP3A4THRB
SCHEMBL99833 0.83 TSHR (0.65) ALDH1A1POLBTSHRCYP3A4THRB
SCHEMBL8246414 0.81 ALDH1A1 (0.53) ALDH1A1POLBTSHRCYP3A4THRB
SCHEMBL31118863 0.81 ALDH1A1 (0.53) ALDH1A1POLBTSHRCYP3A4THRB
SCHEMBL5794414 0.81 TSHR (0.63) ALDH1A1POLBTSHRCYP3A4THRB
SCHEMBL29514652 0.79 TSHR (0.67) POLBTSHRHPGDSRD5A2
SCHEMBL110094 0.79 TSHR (0.67) POLBTSHRHPGDSRD5A2
Potassium Ion SCHEMBL5794413 0.79 ALDH1A1 (0.51) ALDH1A1POLBTSHRCYP3A4THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725548-B1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF ASPARTIC ACETAL CASPASE INHIBITORS VERTEX PHARMA (US) 2015-01-14 EP disclosed
EP-2399915-B1 Process and intermediates for the preparation of aspartic acetal caspase inhibitors VERTEX PHARMA (US) 2014-12-17 EP disclosed
EP-2399916-B1 Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors VERTEX PHARMA (US) 2014-12-10 EP disclosed
CN-103467459-A Processes for preparing compound VERTEX PHARMA 2013-12-25 CN disclosed
CN-102225936-B Processes for producing compound VERTEX PHARMA 2013-09-11 CN disclosed
US-20130066083-A1 PROCESSES AND INTERMEDIATES VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-03-14 US disclosed
US-8293929-B2 Processes and intermediates VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-23 US disclosed
EP-2399916-A1 Process and intermediates for the preparation of aspartic acetal caspase ihnhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-12-28 EP disclosed
EP-2399915-A1 Process and intermediates for the preparation of aspartic acetal caspase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-12-28 EP disclosed
CN-102225936-A Processes for producing compound VERTEX PHARMA 2011-10-26 CN disclosed
CN-1950364-B Process and intermediates for preparing aspartate acetal caspase inhibitors VERTEX PHARMA 2011-06-08 CN disclosed
US-20110071298-A1 Processes and Intermediates VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-24 US disclosed
US-7834200-B2 Processes and intermediates VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-16 US disclosed
US-20090048429-A1 Processes and intermediates VERTEX PHARMACEUTICALS INCORPORATED 2009-02-19 US disclosed
US-7381827-B2 5-Ethoxy-4-(1-(benzyloxycarbonyl)-2-pyrrolidinylcarbonylamino)-5H-furan-2-one; purification by chromatography, selectively crystallization, or dynamic crystallization; useful for preparing caspase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-03 US disclosed
CN-1950364-A Process and intermediates for preparing aspartate acetal caspase inhibitors VERTEX PHARMA (US) 2007-04-18 CN disclosed
EP-1725548-A2 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF ASPARTIC ACETAL CASPASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2006-11-29 EP disclosed
US-20060020016-A1 Processes and intermediates VERTEX PHARMACEUTICALS INCORPORATED 2006-01-26 US disclosed
WO-2005090334-A2 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF ASPARTIC ACETAL CASPASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071298-A1 Processes and Intermediates CASP1, CASP3, CASP5 ALDH1A1 378/4885POLB 1990/4885TSHR 4859/4885
US-20130066083-A1 PROCESSES AND INTERMEDIATES CASP1, CASP3, CASP5 ALDH1A1 378/4885POLB 1990/4885TSHR 4859/4885
US-20090048429-A1 Processes and intermediates CASP1, CASP3, CASP5 ALDH1A1 378/4885POLB 1990/4885TSHR 4859/4885
US-20060020016-A1 Processes and intermediates CASP1, CASP3, CASP5 ALDH1A1 378/4885POLB 1990/4885TSHR 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.